Dose-Dependent Toxicity of a Commercially Available Demineralized Bone Matrix Material

Study Design. A relative risk assessment was performed to determine the safety of three commercially available Grafton demineralized bone matrix quantities used in athymic rats. Objective. To evaluate the possible dose-dependent adverse effects of a commercially available demineralized bone matrix containing glycerol. Summary of Background Data. Commercially available Grafton demineralized bone matrix contains glycerol. The toxic effects of glycerol leading to acute renal failure have been documented. The toxicity of this glycerol-containing substance in higher doses has not been reported. Methods. Three doses of Grafton putty were implanted in the upper hind limb muscles of athymic nude rats. The rats were observed for adverse effects and early death. Histologic studies were performed. Results. All eight of the rats implanted with the highest dose of Grafton putty (0.008 mL/g) died, five of them within 12 hours of implantation and three in 48 to 72 hours. One rat with the intermediate dose (0.004 mL/g) died within 12 hours of implantation. By 72 hours after implantation, three of the six rats (50%) with the intermediate dose had died. All six of the rats receiving the lowest dose (0.002cc/g) survived. The median lethal dose of Grafton putty in athymic rats was estimated to be 0.00469 mL/g body weight. Histologic analysis of the animals that received the high dose showed acute tubular necrosis, probably secondary to rhabdomyolysis. Conclusions. In athymic rats, large amounts of Grafton putty lead to death in a dose-dependent manner. Because the median lethal doses of Grafton putty (0.00469 mL/g) and glycerol (0.00442 mL/g) are comparable, a potential source of toxicity is the glycerol contained in the material. The results of this study suggest that high doses have the potential to cause acute renal failure. The authors suggest that clinical usage of Grafton putty in humans should be limited to no more than 2 mL/kg body weight of this material.

[1]  N. Scarborough,et al.  Allograft bone. The influence of processing on safety and performance. , 1999, The Orthopedic clinics of North America.

[2]  L. Titus,et al.  New formulations of demineralized bone matrix as a more effective graft alternative in experimental posterolateral lumbar spine arthrodesis. , 1999, Spine.

[3]  N. Scarborough,et al.  Osteoinduction of Human Demineralized Bone: Characterization in a Rat Model , 1998, Clinical orthopaedics and related research.

[4]  I. Katkov,et al.  Mouse spermatozoa in high concentrations of glycerol: chemical toxicity vs osmotic shock at normal and reduced oxygen concentrations. , 1998, Cryobiology.

[5]  L. Rhomberg,et al.  Empirical Scaling of Single Oral Lethal Doses Across Mammalian Species Based on a Large Database , 1998, Risk analysis : an official publication of the Society for Risk Analysis.

[6]  H. Wertheim,et al.  Healing response to various forms of human demineralized bone matrix in athymic rat cranial defects. , 1998, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[7]  E. Kharasch,et al.  Anesthetic effects on the glycerol model of rhabdomyolysis-induced acute renal failure in rats. , 1998, Journal of the American Society of Nephrology : JASN.

[8]  K. Chesmel,et al.  Re: Ability of commercial demineralized freeze-dried bone allograft to induce new bone formation (1996;67:918-26) , 1997, Journal of periodontology.

[9]  Fink Rd.  Re: Prevalence of periodontal disease. , 1997 .

[10]  P. Roberts,et al.  Enteral feeding improves outcome and protects against glycerol-induced acute renal failure in the rat. , 1997, American journal of respiratory and critical care medicine.

[11]  Sudhir V. Shah,et al.  Oxidant mechanisms in toxic acute renal failure. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  D. Carnes,et al.  Ability of commercial demineralized freeze-dried bone allograft to induce new bone formation. , 1996, Journal of periodontology.

[13]  T. Yamada.  [Studies on the mechanisms of renal damages induced by nephrotoxic compounds]. , 1995, Nihon hoigaku zasshi = The Japanese journal of legal medicine.

[14]  P. Bruneval,et al.  Role of endothelin in acute renal failure due to rhabdomyolysis in rats. , 1995, The Journal of pharmacology and experimental therapeutics.

[15]  J. Goo,et al.  Doppler Sonography in Experimentally Induced Acute Renal Failure in Rabbits: Resistive Index versus Serum Creatinine Levels , 1995, Investigative radiology.

[16]  I. Lauder,et al.  Treatment of Acute Cortical Infarct With Intravenous Glycerol: A Double‐blind, Placebo‐Controlled Randomized Trial , 1993, Stroke.

[17]  P. Singer,et al.  Hypercaloric glycerol in injured patients. , 1992, Surgery.

[18]  I. Lauder,et al.  Treatment of Acute Cerebral Hemorrhage With Intravenous Glycerol: A Double-Blind, Placebo-Controlled, Randomized Trial , 1992, Stroke.

[19]  I. Lauder,et al.  Investigation of intravascular haemolysis during treatment of acute stroke with intravenous glycerol. , 1990, British journal of clinical pharmacology.

[20]  R. Arowolo,et al.  Toxic effects of glycerol in Swiss albino rats. , 1987, Research communications in chemical pathology and pharmacology.

[21]  P. Wunderlich,et al.  Glycerol and dextran combined in the therapy of acute stroke. A placebo-controlled, double-blind trial with a planned interim analysis. , 1987, Stroke.

[22]  R. Newcombe,et al.  DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS GLYCEROL IN ACUTE STROKE , 1987, The Lancet.

[23]  L. C. Russell,et al.  Glycerol neurolysis: neurophysiological effects of topical glycerol application on rat saphenous nerve. , 1985, Journal of neurosurgery.

[24]  P. Mazur,et al.  Toxic and osmotic effects of glycerol on human granulocytes. , 1984, The American journal of physiology.

[25]  P. Singer,et al.  Effect of glycerol on peripheral nerve: an experimental study. , 1983, Neurosurgery.

[26]  W. Sweet,et al.  Treatment of trigeminal neuralgia and other facial pains by retrogasserian injection of glycerol. , 1981, Neurosurgery.

[27]  M. Nahata,et al.  Glycerol: A Review of Its Pharmacology, Pharmacokinetics, Adverse Reactions, and Clinical Use , 1981, Pharmacotherapy.

[28]  R. Podesta,et al.  The Host-Invader Interplay , 1981 .

[29]  N. Marinovich,et al.  DOUBLE-BLIND TRIAL OF GLYCEROL THERAPY IN EARLY STROKE , 1976, The Lancet.

[30]  W. Deichmann.  Glycerol:—Behavior in the Animal Organism—(A Review of the Literature) , 1940 .

[31]  Wang.  PROSPECTIVE COMPARISON OF COMMERCIALLY AVAILABLE DEMINERALIZED BONE MATRIX FOR SPINAL FUSION , 2001 .

[32]  Z. Gugala,et al.  The cylindrical titanium mesh cage for treatment of a long bone segmental defect: description of a new technique and report of two cases. , 2000, Journal of orthopaedic trauma.

[33]  V. Stefanović,et al.  Protective effect of a bioflavonoid proanthocyanidin-BP1 in glycerol-induced acute renal failure in the rat: renal stereological study. , 1999, Renal failure.

[34]  M. Popovtzer,et al.  Glycerol-induced acute renal failure attenuates subsequent HgCl2-associated nephrotoxicity: correlation of renal function and morphology. , 1998, Renal failure.

[35]  K. Harimoto,et al.  Hepatocyte growth factor in glycerol-induced acute renal failure. , 1997, Nephron.

[36]  M. Perlman,et al.  Uses of Grafton for reconstructive foot and ankle surgery. , 1996, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.

[37]  J. Hughes,et al.  Allograft safety: viral inactivation with bone demineralization. , 1995, Contemporary orthopaedics.

[38]  S. Mackinnon,et al.  Nerve reconstruction with glycerol‐preserved allogenic grafts in the rat, by Wolff, Walter, and Zimmer. Microsurgery 14:315–322, 1993 , 1994 .

[39]  P. Braquet,et al.  Upregulation of renal endothelin receptors in glycerol-induced acute renal failure in the rat. , 1993, Journal of cardiovascular pharmacology.